Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Lexaria Bioscience Corp. (LEXX)
|
Add to portfolio |
|
|
|
| Price: |
$4.39
| | Metrics |
| OS: |
8.09
|
M
| |
|
|
| Market cap: |
$35.5
|
M
| |
|
|
|
Net cash:
|
$539.1
|
k
| |
$0.07
|
per share
|
|
EV:
|
$35
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($7.3)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Aug-31-22 | Aug-31-21 | Aug-31-20 | Aug-31-19 | Aug-31-18 | Aug-31-17 | Aug-31-16 | Aug-31-15 |
| Revenues | 0.3 | 0.7 | 0.4 | 0.2 | 0.4 | 0.1 | 0.0 | 0.1 |
| Revenue growth | -64.7% | 87.9% | 72.7% | -48.6% | 580.9% | 56.3% | -53.6% | |
| Cost of goods sold | 0.1 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 |
| Gross profit | 0.2 | 0.5 | 0.3 | 0.2 | 0.4 | 0.0 | 0.0 | 0.0 |
| Gross margin | 71.9% | 75.7% | 73.7% | 89.7% | 94.2% | 53.3% | -12.0% | -35.8% |
| Selling, general and administrative | | | | | | | | |
| Sales and marketing | | | 0.2 | 0.5 | 0.5 | 0.2 | 0.2 | 0.3 |
| Research and development | 1.8 | 1.3 | 0.4 | 0.6 | 0.5 | 0.1 | 0.0 | 0.1 |
| General and administrative | 5.7 | 5.0 | 0.8 | 0.8 | 0.4 | 0.3 | 0.3 | 0.1 |
| EBITA | -7.4 | -4.2 | -3.7 | -3.5 | -6.3 | -1.8 | -1.2 | -1.9 |
| EBITA margin | -2891.0% | -576.2% | -959.5% | -1564.7% | -1459.2% | -2816.5% | -3043.6% | -2208.0% |
| Amortization of intangibles | | | 0.0 | 0.0 | 0.0 | 0.0 | | |
| EBIT | -7.4 | -4.2 | -3.7 | -3.5 | -6.3 | -1.8 | -1.2 | -1.9 |
| EBIT margin | -2891.0% | -576.2% | -961.3% | -1566.7% | -1459.6% | -2817.9% | -3043.6% | -2208.0% |
| Pre-tax income | -7.4 | -4.2 | -4.0 | -4.2 | -6.6 | -1.9 | -1.3 | -1.9 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | | | | 0.0% | 0.0% | 0.0% | 2.5% |
| Earnings from continuing ops | -7.3 | -4.0 | -3.9 | -4.1 | -6.6 | -1.9 | -1.2 | -1.8 |
| Earnings from discontinued ops | | 0.0 | | | | | | 0.0 |
| Net income | -7.3 | -4.0 | -3.9 | -4.1 | -6.6 | -1.9 | -1.2 | -1.8 |
| Net margin | -2846.3% | -557.2% | -1023.0% | -1841.5% | -1523.0% | -2937.3% | -2983.4% | -2017.8% |
| |
| Diluted EPS | ($1.24) | ($0.94) | ($0.05) | ($0.05) | ($0.09) | ($0.03) | ($0.03) | ($0.05) |
| Shares outstanding (diluted) | 5.9 | 4.2 | 83.2 | 77.8 | 71.0 | 58.8 | 43.8 | 39.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|